At Candriam, we are active owners and debtholders. We exercise our rights when we believe action can enhance long-term value for our clients and ultimate beneficiaries.
Latest insights
6 results found
-
Oncology
ESG, SRI, Oncology
Advances in Healthcare and Oncology: A Pink October Perspective
Good news! The five-year survival rate for women diagnosed with breast cancer in the United States is now 90%[1]. Unfortunately, when looking at other statistics, the outlook worrying: one in eight women will develop an invasive form of breast cancer during their lifetime. In 2020, two million new cancer cases were diagnosed worldwide. Breast cancer is the most common cancer type among women and the second deadliest, following lung cancer. To better understand the urgency of treatments: in 2020, 685,000 women lost their lives from breast cancer.
Malgorzata Kluba, Rudi Van Den Eynde, Oncology, Equities
World Cancer Day 2023
And we would rather not have to go through this – which would mean we won the battle and cancer is curable.
Oncology, Q&A, Rudi Van Den Eynde, Equities
Investing in oncology: forewarned is forearmed
Rudi Van Den Eynde, Head of Thematic Global Equity at Candriam, explains to investors the approach he used to create and develop an investment strategy in the oncology sector.
Oncology
World Cancer Day: How PRISM is helping to Close the Gap
The Candriam Institute provides financial support to the PRecISion Medicine Institute. The PRISM technology aims to save an additional 200,000 lives each year by identifying the unique molecular characteristics of each patient's cancer.
Oncology, ESG, SRI
World Cancer Day: How PRISM is helping to Close the Gap
The Candriam Institute provides financial support to the PRecISion Medicine Institute. The PRISM technology aims to save an additional 200,000 lives each year by identifying the unique molecular characteristics of each patient's cancer. With this information, more targeted treatment can be applied at each step, improving survival rates.
Oncology
Fight against cancer: Let’s write another story together
While cancer is still striking hard and remains among the leading causes of death globally, pharmaceutical innovation is continuing at a high pace. The patients’ survival rate keeps increasing, as is our understanding of the disease and its multiple forms deepens, and as breakthrough therapies are tested and launched.